Odyssey Hits The Mark, SPHS Awaits Data In Q2, TEVA Breathes Easy

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi's (SNY) phase III trial of cholesterol-lowering treatment Praluent in patients undergoing LDL *apheresis therapy has met the primary endpoint.

from RTT - Biotech http://ift.tt/1WKhyfc
via IFTTT